A prospective pilot study by Kang et al. [56], using the same type and amount of radiopharmaceutical [68Ga]FAPI-46 but with different positivity visual criteria (more than twice the intensity of MBP), was addressed to especially identify NSCLC N2 stage, a pivotal aspect in making management plan decisions for surgical candidates. Here, MBP is linked to non-small cell lung carcinoma.